Company intelligence / Profile preview

FixNip

Ownership: Private
Development stage: Other

Overview

FixNip’s Nipple Reconstruction Implant (FixNip NRI™) has demonstrated high patient satisfaction and excellent safety profile in multi-centric safety and efficacy studies. The device provides a minimally invasive solution that maintains natural look and feel over time, addressing loss of nipple projection—a common issue with existing solutions. Early results from European markets are positive, with pivotal clinical trials underway at MD Anderson Cancer Center in Texas as part of US regulatory review

Therapeutic areas: Oncology
Modalities: Devicesilicone implant with a nitinol frame
Industry: Implantable Medical Devices

Partnerships

GC Aesthetics® – exclusive partnership for launch/distribution in Europe and other territories

Beyond the preview

Go deeper on FixNip.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FixNip.

Explore the full profile